In this cohort study of 12,046 patients with cancer and COVID-19, it was discovered that the use of immunotherapy (IO) and other systemic anticancer therapies in combination with baseline immunosuppression was linked to worse outcomes and a higher incidence of cytokine storm in SARS-CoV-2-infected cancer patients.

This study provides evidence that older patients with Binet stage A CLL, including those in the oldest age groups, can receive the Chronic Lymphocytic Leukemia International Prognostic Index (CLL-IPI). Because of the high median age in our study, we were also able to identify a relationship between del(17p) and age, which raises the possibility that age-adjusted prognostic tools could enhance CLL prediction. In cardiology, risk stratifications and recommendations for antilipid treatment have long taken into account the interaction between age and other risk factors for fatal cardiovascular disease, but in CLL, age is typically only considered as an additive factor in prognostic models.

The median PFS and overall survival in the hormone receptor-positive cohort (494; 88.7%) were 23.9 months and 17.5 months, respectively, for the trastuzumab deruxtecan group and 10.1 months and 5.4 months, respectively, for the physician’s choice group. Overall survival was 23.4 months and 16.8 months, respectively, while the median PFS for all patients was 9.9 months for the trastuzumab deruxtecan group and 5.1 months for the physician’s choice group.

What is missing for Dr. Kristen Fuller now? Preserving life. Teaching sufferers and their families about chronic illness. Assisting individuals in changing their lifestyles to lead healthier lives. Observing patients make a full recovery from severe illness. The instinctive knowledge that she was making the world a better place. What doesn’t she miss? The way society views doctors, extreme stress, burnout, sleepless nights, emotional toll, and administrative work.

To gain access to its primary experimental medication for a rare blood cancer and complement Blenrep, currently indicated as a treatment for patients with relapsed or refractory multiple myeloma who received at least four prior therapies, the company decided to purchase American pharmaceutical company Sierra Oncology in April. However, in patients with relapsed or refractory multiple myeloma, Blenrep did not achieve the primary endpoint of progression-free survival, according to a statement from GSK, which saw its shares fall 3% upon the announcement.

According to the researchers who published their findings in JAMA Network Open, the percentage of chronic pain patients using non-drug therapies without opioids remained relatively stable at 20% from 2011 to 2016, but it then increased quickly, reaching 40% in 2019. Non-opioid therapy is preferred for treating chronic pain, according to CDC guidance. However, neither the use of opioids alone nor in combination with non-drug treatments for chronic pain significantly decreased following the 2016 guidance. In fact, while about 3% to 15% of patients used opioids alone, their use increased slightly between 2016 and 2018 (from about 10% to 15% of patients).